About: http://webisa.webdatacommons.org/353824517

Property	Value
http://www.w3.org/1999/02/22-rdf-syntax-ns#type	http://www.w3.org/ns/prov#Entity
http://www.w3.org/ns/prov#value	However, there was a higher rate of serious adverse events in the bevacizumab group compared with the ranibizumab group.
http://www.w3.org/ns/prov#wasQuotedFrom	bmj.com